Warren Buffett Is Selling Apple and Bank of America and Piling Into This Beaten Down Value Stock Instead

Warren Buffett's Berkshire Hathaway continued its net selling streak for an eleventh consecutive quarter, divesting approximately $6.9 billion in Q2, primarily by trimming significant stakes in Apple and Bank of America. This strategic selling capitalizes on a favorable 21% corporate tax rate and perceived high market valuations for these long-held positions. Concurrently, Berkshire made a notable contrarian investment, purchasing an estimated $2 billion in UnitedHealth Group, a healthcare giant facing short-term pressures like a DOJ investigation and reduced guidance, but which Buffett likely views as a deeply undervalued opportunity given its strong competitive moats and long-term growth prospects.

Analysis

Berkshire Hathaway maintained its position as a net seller of equities for the eleventh consecutive quarter, divesting a net $6.9 billion in Q2. The activity was primarily driven by the continued trimming of its major holdings in Apple (AAPL) and Bank of America (BAC), with sales since mid-2023 now amounting to 69% and 41% of its respective stakes. This strategic profit-taking appears motivated by two factors: elevated valuations, with Apple's forward P/E sitting between 27-29 and Bank of America's price-to-tangible book value exceeding 1.7, and a desire to realize gains under the current 21% corporate tax rate, which management views as potentially unsustainable. In a significant counter-cyclical move, Berkshire deployed an estimated $2 billion into UnitedHealth Group (UNH), a healthcare major facing severe headwinds. UNH's stock has fallen over 60% from its peak amid a DOJ investigation, high medical utilization rates that have compressed its net margin from 4.3% to 3.1% year-over-year, and a sharp downward revision of its full-year EPS guidance to 'at least' $16 from a prior $27.66. Berkshire's investment signals a deep-value thesis, predicated on UNH's durable competitive moats, significant scale, strong balance sheet, and a valuation of approximately 16 times 2026 estimated earnings.

Key Decisions for Investors

• Berkshire's persistent net selling and express concerns over high market valuations serve as a cautionary signal for investors to review their own portfolios for overextended positions.
• The significant reduction in Apple and Bank of America stakes suggests a premier value investor sees limited upside from current levels, warranting a thesis re-evaluation for shareholders in those companies.
• The substantial contrarian investment in UnitedHealth Group highlights a potential deep-value opportunity for investors with a higher risk tolerance, but requires careful monitoring of the ongoing DOJ investigation and medical cost trends.
• The recent 10% decline in Berkshire Hathaway's stock, attributed to CEO succession news rather than fundamental performance, may present an entry point for long-term investors confident in the firm's post-Buffett future.